Previous Close
Price To Book
Market Cap 0
Shares 0
Volume 0
Short Ratio
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completion of enrolment announced March 4, 2019. Further data due late-2019 or early 2020.
RX-3117 in combination with Abraxane
First-line pancreatic cancer
Phase 2a updated preliminary data presented at ASCO GU February 15, 2019. 1/31 ORR/CR.
Bladder cancer
Phase 2 enrolment stopped - noted December 2018. Will focus on combo trial with Keytruda to be initiated 2H 2019.
Triple negative breast cancer
Noted February 8, 2018 that development will be discontinued.
Renal cell carcinoma (RCC) - cancer
Phase 2 trial planned.
Hepatocellular carcinoma (HCC)

Latest News

  1. Rexahn Announces Move to Nasdaq
  2. Rexahn Pharmaceuticals, Inc.'s (NYSEMKT:RNN) Profit Outlook
  3. Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results
  4. China Licensing Deal Sends Nanocap Rexahn Pharma Rocketing Higher
  5. Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China
  6. Rexahn Effects 1-for-12 Reverse Stock Split
  7. Rexahn Announces Reverse Stock Split
  8. Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting
  9. Rexahn Pharmaceuticals Reports 2018 Financial Results
  10. Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients
  11. Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
  12. Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium
  13. What You Must Know About Rexahn Pharmaceuticals, Inc.’s (NYSEMKT:RNN) Beta Value
  14. Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium
  15. Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types
  16. Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings
  17. Rexahn Announces Pricing of Public Offering of Common Stock and Warrants
  18. Rexahn Announces Proposed Public Offering of Common Stock and Warrants
  19. Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium
  20. The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug